The FDA approved Pfizer's maternal vaccine to protect newborns from RSV. Courtesy Pfizer Still, the vaccine, given from 32 to 36 weeks of gestational age, does not provide long-term protection.

An advisory panel for the U.S. Centers of Disease Control and Prevention on Friday recommended that a vaccine for respiratory ...

The CDC specifically recommended that expectant mothers 32 to 36 weeks into their pregnancy receive the shot, Pfizer's ...

A Pfizer Inc. PFE, -0.48% vaccine designed to protect babies from respiratory syncytial virus, or RSV, got a green light Monday from the U.S. Food and Drug Administration — a key milestone for ...

The Food and Drug Administration (FDA) has approved the first vaccine for pregnant women to prevent RSV in infants, the agency announced on Monday. Abrysvo has been approved as a maternal vaccine to ...

A key CDC advisory committee Friday voted to recommend infant immunization against RSV via Pfizer's maternal vaccination.

The Food and Drug Administration approved Abrysvo, Pfizer’s respiratory syncytial virus (RSV) vaccine, for use in pregnant individuals to prevent lower respiratory tract disease (LRTD) and severe LRTD ...

PHILADELPHIA (CBS) -- A new weapon to fight a contagious respiratory virus that strikes young children. The first vaccine to protect infants from RSV was just approved by the FDA. It would be ...

One month after the FDA’s initial approval, the CDC voted to recommend Pfizer’s RSV vaccine for pregnant people who are ...

Women may soon have a vaccine they can take during a pregnancy to help protect their newborn from respiratory syncytial virus ...